Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Another CRISPR approval not likely 'any time soon' - report (NASDAQ:CRSP)seekingalpha.
Arizona State Retirement System’s holdings in CRISPR Therapeutics were worth $850,000 as of its most recent SEC filing.
Bank Julius Baer & Co. Ltd Zurich lifted its position in shares of CRISPR Therapeutics by 394.5% in the second quarter.
Country Trust Bank purchased a new position in CRISPR Therapeutics during the third quarter valued at $33,000.
Source: https://www.etfdailynews.com/2023/01/22/cwm-llc-reduces-stake-in-crispr-therapeutics-ag-nasdaqcrsp/
CRISPR is on the cusp of potentially having the first FDA approved therapy using gene editing, CASGEVY (exa-cel) - the FDA rules on this on December 8, 2023.
CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $72.00.
“Developing a safe and efficient delivery system for the CRISPR genome editor is essential for clinical translation,” says Gong.
Source: https://news.wisc.edu/uw-researchers-will-trial-gene-editing-therapy-to-treat-blindness/
Finally, Cibc World Market Inc. raised its position in CRISPR Therapeutics by 49.3% during the 1st quarter.
For example, consider the latest and greatest genetic tool, called CRISPR.
Source: https://www.lewrockwell.com/2023/06/jon-rappoport/passport-to-the-brave-new-world-the-vaccine/
Fortunately, CRISPR, or clustered regularly interspaced short palindromic repeats, can potentially treat all of them.
Source: https://investorplace.com/2023/03/the-3-best-crispr-stocks-to-buy-now-before-they-skyrocket/
How to label and describe CRISPR products is also controversial.
In 2017, researchers in China created healthy mice with two mothers, but it involved a tremendous amount of gene editing with CRISPR, making it impractical to use for anything other than research.
Source: https://www.bostonherald.com/2023/04/10/two-dads-one-baby-gene-technique-works-in-mice/
In addition, Cantor Fitzgerald analyst Olivia Brayer recently initiated coverage of CRISPR with a “buy” rating.
Source: https://investorplace.com/2023/04/why-are-gene-editing-stocks-crsp-edit-ntla-stock-up-today/
In other CRISPR Therapeutics news, CEO sold 25,000 shares of the stock in a transaction dated Monday, February 27th.
Mizuho began coverage on shares of CRISPR Therapeutics ( in a research note issued to investors on Tuesday, reports.
Source: https://www.etfdailynews.com/2023/09/30/mizuho-initiates-coverage-on-crispr-therapeutics-nasdaqcrsp/
Sanford C. Bernstein assumed coverage on CRISPR Therapeutics in a report on Tuesday, March 21st.
Sanford C. Bernstein initiated coverage on CRISPR Therapeutics in a report on Tuesday, March 21st.
Scientists have made a significant breakthrough in the fight against avian influenza, using CRISPR gene-editing technology to create chickens resistant to the virus.
Source: https://www.baltimoregaylife.com/making-chickens-more-resistant-to-bird-flu-with-crispr-technology/
SG Americas Securities LLC boosted its holdings in shares of CRISPR Therapeutics by 112.9% in the fourth quarter.
The bottom line is CRISPR could usher in a new era of transformative medicine we’ve never seen before.
Source: https://investorplace.com/2023/03/the-3-best-crispr-stocks-to-buy-now-before-they-skyrocket/